Impact of Transcutaneous Vagal Nerve Stimulation on Stress Response in Major Depression

Last updated: November 18, 2024
Sponsor: Massachusetts General Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Depression

Mood Disorders

Depression (Adult And Geriatric)

Treatment

Sham tVNS

active tVNS

Clinical Study ID

NCT04448327
2020P001212
1U54MH118919-01A1
  • Ages 50-65
  • All Genders

Study Summary

This study will identify the sex-dependent impact of expiratory-gated transcutaneous vagus nerve stimulation (tVNS) on the modulation of the stress response circuitry and associated physiology in major depressive disorder (MDD). We will evaluate a sample of 80 adults with recurrent MDD randomized to receive active or sham expiratory-gated tVNS during a functional magnetic resonance imaging (fMRI) session, with simultaneous mood and physiological assessments. We hypothesize that expiratory-gated tVNS will effectively modulate, in a sex-dependent manner, specific brainstem-cortical pathways of the stress circuitry and attenuate physiological deficits in MDD.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Current or past diagnosis of recurrent Major Depressive Disorder

Exclusion

Exclusion Criteria:

  • History of neuroleptic use

  • Any psychiatric disorder involving a history of psychosis (e.g. schizophrenia,bipolar I disorder)

  • Active suicidal ideation with intent and/or plan or history of a suicide attemptwithin the last year

  • Moderate or severe substance use disorder within the past 12 months

  • Diagnosis of significant cardiovascular or cerebrovascular disease (e.g. congestiveheart failure, stroke, cardiac conduction disorders, history of asystole ornon-sustained ventricular tachycardia)

  • Diseases affecting the CNS (e.g. MS, epilepsy, neurodegenerative diseases, etc.)

  • Traumatic brain injury with cognitive sequelae

  • MRI or tVNS contraindications (e.g. claustrophobia, metallic implants or devices)

  • Pregnancy (uncommon, given the age of this cohort is 50+ years) due to unknownhealth risks for the fetus

Study Design

Total Participants: 80
Treatment Group(s): 2
Primary Treatment: Sham tVNS
Phase:
Study Start date:
January 29, 2021
Estimated Completion Date:
December 31, 2025

Study Description

Major depressive disorder (MDD) is a leading cause of morbidity and disability worldwide with abnormalities in the stress response circuitry and central autonomic network. Many of these regions are sexually dimorphic and related with sex differences in mood and hypothalamic-pituitary-adrenal (HPA) axis modulation, the dysregulation of which is associated with alterations of hormone and immune responses to stress, autonomic dysfunction and increased cardiovascular risk. The primary goal of this study is to use non-invasive neuromodulatory stimulation of the vagus to target the circuitry associated with stress-immune function and map its neuroanatomic and physiological effects in MDD by sex. Vagal nerve stimulation (VNS), FDA-approved for MDD, modulates brain circuitry implicated in mood/anxiety and autonomic regulation, however, it is implanted and thus invasive. We propose the use of a physiologically-enhanced transcutaneous VNS (tVNS) as a low risk, non-invasive, and inexpensive alternative. While tVNS has had beneficial effects on depressive symptomatology and autonomic regulation, current stimulation parameters are based on historical iVNS data that included mostly male populations. We propose that tVNS effects on the regulation of specific brainstem-cortical pathways is modulated by sex. Moreover, as the dorsal medullary vagal system operates in tune with respiration, we recently demonstrated that tVNS can be optimized by gating stimulation to respiration. Thus, this study proposes to identify the sex-dependent impact of expiratory-gated tVNS on the modulation of stress response circuitry alterations and physiological dysregulation of recurrent MDD. We will evaluate a sample of 80 adults with recurrent MDD randomized to receive active tVNS or sham stimulation during a functional magnetic resonance imaging (fMRI) session. The fMRI session will include a stress challenge designed to elicit a sympatho-excitatory state, with simultaneous mood and physiological assessments, including hormonal and dynamic cardiovagal heart rate variability (HRV) evaluations. We hypothesize that expiratory-gated tVNS will effectively modulate specific brainstem-cortical pathways of the stress response circuitry and will attenuate physiological deficits of recurrent MDD patients. We further hypothesize that tVNS will impact brain activity and physiology in sex-dependent ways.

Connect with a study center

  • Massachusetts General Hospital

    Charlestown, Massachusetts 02129
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.